BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 221 filers reported holding BRIDGEBIO PHARMA INC in Q1 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,957 | +53.3% | 643 | 0.0% | 0.00% | – |
| Q2 2023 | $11,061 | +3.8% | 643 | 0.0% | 0.00% | – |
| Q1 2023 | $10,660 | +84.3% | 643 | -15.3% | 0.00% | – |
| Q4 2022 | $5,783 | -17.4% | 759 | +4.3% | 0.00% | – |
| Q3 2022 | $7,000 | 0.0% | 728 | 0.0% | 0.00% | – |
| Q2 2022 | $7,000 | +133.3% | 728 | +225.0% | 0.00% | – |
| Q1 2022 | $3,000 | +200.0% | 224 | +173.2% | 0.00% | – |
| Q4 2021 | $1,000 | -99.6% | 82 | -98.5% | 0.00% | – |
| Q3 2021 | $249,000 | -21.2% | 5,338 | +2.8% | 0.00% | – |
| Q2 2021 | $316,000 | -15.1% | 5,194 | -13.8% | 0.00% | – |
| Q1 2021 | $372,000 | +24.4% | 6,028 | +43.7% | 0.00% | – |
| Q4 2020 | $299,000 | +29800.0% | 4,196 | +11555.6% | 0.00% | – |
| Q3 2020 | $1,000 | 0.0% | 36 | -12.2% | 0.00% | – |
| Q2 2020 | $1,000 | – | 41 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $100,609,513 | 48.41% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $514,990,899 | 15.50% |
| M28 Capital Management LP | 304,700 | $5,051,926 | 5.71% |
| Cormorant Asset Management, LP | 4,557,414 | $75,562 | 4.98% |
| Octagon Capital Advisors LP | 1,338,160 | $22,186,693 | 3.19% |
| Ikarian Capital, LLC | 594,686 | $9,859,894 | 2.24% |
| Affinity Asset Advisors, LLC | 389,800 | $6,462,884 | 2.13% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $441,376,031 | 2.07% |
| Ikarian Capital, LLC | 549,600 | $9,112,368 | 2.07% |
| Affinity Asset Advisors, LLC | 320,000 | $5,305,600 | 1.75% |